BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Retina
,
Pharmacogenetics
,
Tamoxifen
,
rs7903146
,
PBX1
,
Coagulation
,
Ischemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
loxapine
Summary
General Info
Curated Studies
Most Correlated Studies
Cerebrocortical cells treated with blood-brain barrier penetrant clinic-tested drugs
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Drug target sets for approved compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
Loxapine P-glycoprotein interactions in vitro.
Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.
Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
In vitro aerosol characterization of Staccato(®) Loxapine.
Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Staccato Loxapine Single Dose PK
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Staccato Loxapine in Migraine (in Clinic)
Staccato Loxapine Multidose PK
Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ